Immunotherapy for malignant mesothelioma: reality check

Expert Review of Anticancer Therapy

Volumn 16, Issue 11, 2016, Pages 1167-1176

  Thapa, Bibhusal ^a,b   Watkins, D Neil ^c   John, Tom ^b,d,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d AUSTIN HEALTH   (Australia)

^e LA TROBE UNIVERSITY   (Australia)

Author keywords

check point inhibition; immunotherapy; Mesothelioma; PD L1; therapeutic vaccines

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AVELUMAB; BETA INTERFERON; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DURVALUMAB; EPIRUBICIN; GALINPEPIMUT S; GAMMA INTERFERON; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PEMETREXED; TICILIMUMAB; TUMOR VACCINE;

ADOPTIVE TRANSFER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL THERAPY; CYTOREDUCTIVE SURGERY; DENDRITIC CELL; DRUG EFFICACY; FOLLOW UP; HUMAN; IMMUNE EVASION; MESOTHELIOMA; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

EID: 84991725967     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1080/14737140.2016.1241149     Document Type: Review

References (92)

1. V.Delgermaa, K.Takahashi, E.-K.Park, et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):716–724.
2. E.-K.Park, K.Takahashi, T.Hoshuyama, et al. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect. 2011;119(4):514–518.
3. E.K.Park, D.H.Yates, R.A.Hyland, et al. Asbestos exposure during home renovation in New South Wales. Med J Aust. 2013;199(6):410–413.
4. C.Blomberg, J.Nilsson, G.Holgersson, et al. Randomized trials of systemic medically-treated malignant mesothelioma:a systematic review. Anticancer Res. 2015;35(5):2493–2501.
5. R.K.Goudar Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma. Ther Clin Risk Manag. 2008;4(1):205–211.
6. G.Zalcman, J.Mazieres, J.Margery, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS):a randomised, controlled, open-label, phase 3 trial. Lancet. 2015;6736(15):1–10.
7. L.Calabrò, A.Morra, E.Fonsatti, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma:an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013 Oct;14(11):1104–1111.• Initial results of checkpoint therapy in MM.
8. L.Calabrò, A.Morra, E.Fonsatti, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma:an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015 Apr;3(4):301–309.• Results of intensified dosage regimen of tremelimumab in MM.
9. B.F.Zamarron, W.Chen. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7(5):651–658.
10. D.S.Vinay, E.P.Ryan, G.Pawelec, et al. Immune evasion in cancer:mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35:S185–98.
11. S.I.Grivennikov, F.R.Greten, M.Karin. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899.
12. J.F.M.Jacobs, S.Nierkens, C.G.Figdor, et al. Regulatory T cells in melanoma:the final hurdle towards effective immunotherapy? Lancet Oncol. 2012;13(1):32–42.
13. W.Zou. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295–307.
14. L.P.Seung, D.Rowley, P.Dubey, et al. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci U S A. 1995;92(14):6254–6258.
15. D.H.Munn, M.D.Sharma, J.R.Lee, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002;297(5588):1867–1870.
16. F.Garrido, F.Ruiz-Cabello, T.Cabrera, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today. 1997;18(2):89–95.
17. D.J.Hicklin, F.M.Marincola, S.Ferrone. HLA class I antigen downregulation in human cancers:T-cell immunotherapy revives an old story. Mol Med Today. 1999;5(4):178–186.
18. R.L.Elliott. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005;23(9):2078–2093.
19. M.H.Lind, B.Rozell, R.P.Wallin, et al. Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-kappaB inhibition. Proc Natl Acad Sci U S A. 2004;101(14):4972–4977.
20. G.Driessens, J.Kline, T.F.Gajewski. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009;229(1):126–144.
21. W.Hwu, S.L.Topalian, P.Hwu, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455–2465.
22. Y.Pico de Coaña, A.Choudhury, R.Kiessling Checkpoint blockade for cancer therapy:revitalizing a suppressed immune system. Trends Mol Med. 2015;21(8):482–491.
23. E.Marcq, P.Pauwels, J.P.Van Meerbeeck, et al. Targeting immune checkpoints:new opportunity for mesothelioma treatment? Cancer Treat Rev. 2015 Dec;41(10):914–924.
24. G.Parmiani, C.Maccalli, M.Maio. Integrating immune checkpoint blockade with anti-neo/mutated antigens reactivity to increase the clinical outcome of immunotherapy. Vaccines. 2015;3(2):420–428.
25. R.Bueno, E.W.Stawiski, L.D.Goldstein, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407–416.•• Details the mutational landscape in MM.
26. F.Marmé. Immunotherapy in breast cancer. Oncol Res Treat. 2016;39(6):335–345.
27. N.Yamada, S.Oizumi, E.Kikuchi, et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010 Oct;59(10):1543–1549.
28. M.Anraku, K.S.Cunningham, Z.Yun, et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2008 Apr;135(4):823–829.
29. J.G.Aerts, L.A.Lievense, H.C.Hoogsteden, et al. Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Transl Lung Cancer Res. 2014;3(1):34–45.
30. P.Astoul, D.Picat-Joossen, J.R.Viallat, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma:a phase II study. Cancer. 1998;83(10):2099–2104.
31. C.W.Mulatero, R.T.Penson, D.Papamichael, et al. A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer. 2001;31(1):67–72.
32. M.Lucchi, A.Chella, F.Melfi, et al. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardio-thoracic Surg. 2007;31(3):529–534.
33. C.Boutin, E.Nussbaum, I.Monnet, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer. 1994;74(9):2460–2467.
34. D.H.Sterman, A.Recio, R.G.Carroll, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions:high rate of antitumor immune responses. Clin Cancer Res. 2007;13(15):4456–4466.
35. D.H.Sterman, A.Recio, A.R.Haas, et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther. 2010;18(4):852–860.
36. D.H.Sterman, A.Haas, E.Moon, et al. A trial of intrapleural adenoviral-mediated interferon-α2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med. 2011;184(12):1395–1399.
37. J.P.Hegmans, J.D.Veltman, M.E.Lambers, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010;181(12):1383–1390.
38. R.Cornelissen, J.P.Hegmans, A.P.Maat, et al. Extended tumor control after dendritic cell vaccination with low dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med. 2015;14(C):1–40.
39. A.Powell, J.Creaney, S.Broomfield, et al. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer. 2006;52(2):189–197.
40. L.M.Krug, T.Dao, A.B.Brown, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother. 2010;59(10):1467–1479.
41. M.G.Zauderer, T.Dao, V.W.Rusch, et al. Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy. J Clin Oncol. 2016;34(suppl):abstr:8519.
42. M.Kalos, B.L.Levine, D.L.Porter, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
43. D.R.Leach, M.F.A.J.Krummel. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–1736.
44. C.Guntermann, D.R.Alexander. CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation:a potential role for tyrosine phosphatases. J Immunol. 2002;168(9):4420–4429.
45. X.B.Wang, Z.Z.Fan, D.Anton, et al. CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation. BMC Immunol. 2011;12:21.
46. R.Li, N.Perez, S.Karumuthil-Melethil, et al. Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+ and CD4+CD25- TGF-beta 1+ adaptive regulatory T cells. J Immunol. 2007;179(8):5191–5203.
47. U.1.Grohmann, C.Orabona, F.Fallarino, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002;3(11):1097–1101.
48. Y.Pico de Coaña, I.Poschke, G.Gentilcore, et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res. 2013;1(3):158–162.
49. A.Tarhini, H.Edington, L.H.Butterfield, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014;9(2):e87705.
50. A.Ribas. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012 Jun 28;366(26):2517–2519.
51. P.Attia, G.Q.Phan, A.Maker, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23(25):6043–6053.
52. C.Robert, L.Thomas, I.Bondarenko, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526.
53. H.L.Kindler, A.Scherpereel, L.Calabrò, et al. Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM):results from the global, double-blind, placebo-controlled DETERMINE study. J Clin Oncol. 2016;34(suppl):abstr8502.•• Large trial of tremelimumab in MM-negative study.
54. Y.Agata, A.Kawasaki, H.Nishimura, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765–772.
55. T.Okazaki, T.Honjo. PD-1 and PD-1 ligands:from discovery to clinical application. Int Immunol. 2007;19(7):813–824.
56. H.Dong, S.E.Strome, D.R.Salomao, et al. Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion. Nat Med. 2002;8(8):739–800.
57. M.Ishida, Y.Iwai, Y.Tanaka, et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett. 2002;84(1):57–62.
58. R.H.Thompson, S.M.Kuntz, B.C.Leibovich, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381–3385.
59. S.Cedrés, S.Ponce-Aix, J.Zugazagoitia, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One. 2015 Jan;10(3):e0121071.• Initial report of PD-L1 expression in MM.
60. A.S.Mansfield, A.C.Roden, T.Peikert, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014;9(7):1036–1040.• Initial report of PD-L1 in MM.
61. S.L.Topalian, M.Sznol, D.F.McDermott, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–1030.
62. R.S.Herbst, J.-C.Soria, M.Kowanetz, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 26;515(7528):563–567.
63. J.R.Brahmer, S.S.Tykodi, L.Q.M.Chow, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465.
64. E.J.Lipson, W.H.Sharfman, C.G.Drake, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19(2):462–468.
65. O.Hamid, C.Robert, A.Daud, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–144.
66. Alley EW, Molife RL, Santoro A, et al. Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma:Preliminary results from KEYNOTE-028 [Abstract]. In:Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18–22. Philadelphia (PA):AACR; 2015. Abstract nr CT103. (Results of anti PD-1 therapy in MM)• Results of anti-PD-1 therapy in MM.
67. Quispel-Janssen J, Zimmerman M, Buikhuisen W, et al. Nivolumab in malignant pleural mesothelioma (NIVOMES):An interim analysis [Abstract]. In:Proceedings of the 13th International Conference of the International Mesothelioma Interest Group; 2016 May 1–4. Birmingham:IMIG; 2016. Abstract nr 284.
68. R.Hassan, A.Thomas, M.R.Patel, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial:safety, clinical activity, and PD-L1 expression. J Clin Oncol. 2016;34(suppl):abstr8503.• Initial results of anti-PD-L1 therapy in MM.
69. L.Wu, Z.Yun, T.Tagawa, et al. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther. 2012;11(8):1809–1819.
70. G.Manson, J.Norwood, A.Marabelle, et al. Biomarkers associated with checkpoint inhibitors. Ann Oncol. 2016;33:1–8.
71. E.B.Garon, N.A.Rizvi, R.Hui, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015 May 21;372(21):2018–2028.
72. L.Carbognin, S.Pilotto, M.Milella, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1):sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10(6):e01300142.
73. C.Robert, G.V.Long, B.Brady, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330.
74. C.Robert, J.Schachter, G.V.Long, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.
75. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
76. K.M.Mahoney, M.B.Atkins. Prognostic and predictive markers for the new immunotherapies. Oncology. 2014;28(Suppl 3):39–48.
77. J.Larkin, V.Chiarion-Sileni, R.Gonzalez, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
78. H.J.Hammers, E.R.Plimack, B.I.Rini, et al. Expanded cohort results from CheckMate 016:a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2015;33(suppl); abstr 4516.
79. N.A.Rizvi, S.N.Gettinger, J.W.Goldman, et al. Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC). J Thorac Oncol. 2015;10(suppl2):S176.
80. A.J.Van den Eertwegh, J.Versluis, H.P.van den Berg, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer:a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):509–517.
81. R.A.Madan, M.Mohebtash, P.M.Arlen, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer:a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501–508.
82. D.T.Le, E.Lutz, J.N.Uram, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36(7):382–389.
83. M.R.Crittenden, T.Savage, B.Cottam, et al. The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor. PLoS One. 2013;8(7):e69527.
84. C.Jackaman, D.Majewski, S.A.Fox, et al. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo. Cancer Immunol Immmunother. 2012;61(12):2343.
85. M.Z.Dewan, A.E.Galloway, N.Kawashima, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379–5388.
86. Z.G.Fridlender, J.Sun, S.Singhal, et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther. 2010;18(11):1947–1959.
87. J.D.Veltman, M.E.H.Lambers, M.Van Nimwegen, et al. Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activitys. J Biomed Biotechnol. 2010;2010:798467.
88. W.J.Lesterhuis, J.Salmons, A.K.Nowak, et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One. 2013;8(4):1–8.
89. A.K.Nowak, A.M.Cook, A.M.McDonnell, et al. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol. 2015;26(12):2483–2490.
90. R.M.Wong, I.Ianculescu, S.Sharma, et al. Immunotherapy for malignant pleural mesothelioma current status and future prospects. Am J Respir Cell Mol Biol. 2014;50(5):870–875.
91. R.J.Kruklitis, S.Singhal, P.Delong, et al. Immuno-gene therapy with interferon-β before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg. 2004;127(1):123–130.
92. S.Mukherjee, D.Nelson, S.Loh, et al. The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Ther. 2001;8(8):580–588.